S&P Futures
3,936.50 +20.25 (+0.52%) Dow Futures
31,604.00 +117.00 (+0.37%) Nasdaq Futures
12,222.50 +82.00 (+0.68%) Russell 2000 Futures
1,770.70 +9.00 (+0.51%) Crude Oil
107.27 -0.35 (-0.33%) Gold
1,841.10 +10.80 (+0.59%)
Alnylam Pharmaceuticals, Inc. (ALNY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 146.30 |
| Open | 147.68 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1100 |
| Day's Range | 144.38 - 148.25 |
| 52 Week Range | 117.58 - 212.00 |
| Volume | |
| Avg. Volume | 892,846 |
| Market Cap | 17.641B |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.13 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 208.20 |
- Investopedia
A Look Into Foreign Direct Investment Trends
Foreign direct investments play an important role as an indicator of a healthy economy in terms of economic growth and long-term capital movement.
- American City Business Journals
The Petri Dish: Amylyx, Alnylam net drug approvals
The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings. Canada approves Amylyx drug Amylyx Pharmaceuticals Inc. (Nasdaq: AMLX) scored its first-ever approval from Health Canada for its amyotrophic lateral sclerosis (ALS) drug Albrioza.
- Zacks
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
